Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Biguanides Market Expected to Grow Between 2025 And 2029?

The biguanides market has experienced consistent expansion in the past few years. Its size is predicted to rise from $4.96 billion in 2024 to $5.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. This historical growth can be traced back to the higher demand for oral hypoglycemic medications, the growing geriatric population, the increasing rate of obesity, and heightened consciousness about diabetes treatment.

What Growth Rate Is Anticipated for the Biguanides Market in the Coming Years?

Stepping into the next few years, the biguanides market is projected to witness sustained growth and is predicted to reach a market size of $5.98 billion by 2029, with a compound annual growth rate (CAGR) of 3.7%. This estimated growth during the forecast period can be credited to factors like increased adoption of combined therapy strategies, advancements in drug administration techniques, higher spending on research initiatives, increased medical expenditure, and the growing application scope in treating polycystic ovary syndrome. Noteworthy trends in the projection period comprise the growing emphasis on creating sustained-release formulations, rising inclination towards fixed-dose combination therapies, widening application in cancer treatments, and the arrival of new biguanides featuring enhanced efficiency and safety.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15735&type=smp

Who Are the Leading Companies in the Biguanides Market?

Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd., Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Shionogi & Co Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc., Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

What Are the Key Drivers of the Biguanides Market?

The biguanides market is predicted to grow due to the increasing prevalence of diabetes. Diabetes, a chronic metabolic disorder marked by elevated blood sugar levels, stems from the body’s insufficient insulin production. The surge in diabetes cases can be attributed to factors such as lifestyle modifications, an aging population, inherent genetic risks, enhanced diagnostic abilities, and environmental impacts. Biguanides like metformin counteract diabetes by enhancing insulin receptiveness, reducing liver glucose production, and decreasing blood sugar levels in people with type 2 diabetes. As per data from the Office for Health Improvement & Disparities in the UK, between March 2022 and March 2023, the percentage of type 1 diabetes patients receiving all eight suggested care procedures increased by 22%, and for type 2 diabetes, it rose by 21%. Moreover, the proportion reaching the target HbA1c levels climbed to an all-time high of 37.9%. As a result of this increasing diabetes prevalence, the biguanides market is witnessing substantial growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15735&type=smp

What Are the Key Market Segments in the Biguanides Industry?

The biguanides market covered in this report is segmented –

1) By Type: Metformin, Phenformin, Other Types

2) By Dosage Form: Tablets, Oral Solutions

3) By Formulation: Immediate Release, Extended Release

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

2) By Phenformin: Phenformin Hydrochloride

3) By Other Types: Buformin, Metformin Combinations

What Are the Latest Trends in the Biguanides Market?

Key biguanide market players are prioritizing the development of innovative solutions, such as extended-release biguanide medications, with an aim to improve patient compliance, enhance therapeutic efficacy, and minimize side effects. An extended-release biguanide is designed to gradually discharge its active substance, thereby maintaining stable blood levels and facilitating better glycemic management for individuals with diabetes, thus improving adherence to therapy. To illustrate, Dr. Reddy’s Laboratories, a biotech firm based out of India, in August 2023, introduced saxagliptin and metformin hydrochloride extended-release drugs. These drugs are a generic variant of KOMBIGLYZE XR, sanctioned by the USFDA, which merges saxagliptin, a DPP-4 obstructer, with metformin, a biguanide. They are engineered to augment glycemic regulation in adults suffering from type 2 diabetes mellitus and are recommended to be used in conjunction with diet and physical activity. The extended-release formulation enhances patient compliance and efficacy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biguanides-global-market-report

What Are the Key Regional Markets in the Biguanides Industry?

Asia-Pacific was the largest region in the biguanides market in 2023. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15735

This Report Delivers Insight On:

1. How big is the biguanides market, and how is it changing globally?

2. Who are the major companies in the biguanides market, and how are they performing?

3. What are the key opportunities and risks in the biguanides market right now?

4. Which products or customer segments are growing the most in the biguanides market?

5. What factors are helping or slowing down the growth of the biguanides market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model